Cargando…

MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid

The identification of reliable biomarkers for Alzheimer’s disease (AD) remains challenging. Recently, abnormal levels of microRNAs (miRNAs) miR-27a, miR-29a, miR-29b, and miR-125b in cerebrospinal fluid (CSF) of AD patients were reported. We aimed to confirm the biomarker potential of these miRNAs f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Mareike, Jäkel, Lieke, Bruinsma, Ilona B., Claassen, Jurgen A., Kuiperij, H. Bea, Verbeek, Marcel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902829/ https://www.ncbi.nlm.nih.gov/pubmed/25895659 http://dx.doi.org/10.1007/s12035-015-9156-8

Ejemplares similares

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy
por: Marques, Tainá M., et al.
Publicado: (2016)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
por: Marques, Tainá M., et al.
Publicado: (2018)

Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach
por: Marques, Tainá M., et al.
Publicado: (2021)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
por: Santaella, Anna, et al.
Publicado: (2020)

Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
por: Vervuurt, Marc, et al.
Publicado: (2023)

Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
por: Jäkel, Lieke, et al.
Publicado: (2020)

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood‐brain barrier
por: Biemans, Elisanne A.L.M., et al.
Publicado: (2016)

White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers
por: van Waalwijk van Doorn, Linda J.C., et al.
Publicado: (2021)

A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example
por: Herbert, Megan K., et al.
Publicado: (2015)

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
por: Jäkel, Lieke, et al.
Publicado: (2019)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
por: Slats, Diane, et al.
Publicado: (2010)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics
por: Liu, Ping, et al.
Publicado: (2023)

Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease
por: ZHU, YAN, et al.
Publicado: (2015)

Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage
por: Jäkel, Lieke, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders
por: Constantinescu, Radu, et al.
Publicado: (2013)

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
por: Gui, YaXing, et al.
Publicado: (2015)

Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease
por: Geijselaers, Stefan L.C., et al.
Publicado: (2017)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer’s Disease
por: McKeever, Paul M., et al.
Publicado: (2018)

Cerebrospinal Fluid Glucose and Lactate: Age-Specific Reference Values and Implications for Clinical Practice
por: Leen, Wilhelmina G., et al.
Publicado: (2012)

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid
por: Hendrickson, Ronald C., et al.
Publicado: (2015)

Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer's disease
por: Derkow, Katja, et al.
Publicado: (2018)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Jia, Longfei, et al.
Publicado: (2021)

Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer’s Disease and Frontotemporal Dementia
por: Tan, Yi Jayne, et al.
Publicado: (2021)

Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment
por: Wassenberg, Tessa, et al.
Publicado: (2021)

Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
por: Silverberg, Gerald, et al.
Publicado: (2006)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease
por: Barichello, Tatiana, et al.
Publicado: (2019)

Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lim, Bryant, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dabjej0s2jmlsvqic9csqfuc9h